Table 5.
Antifungal susceptibility profile of Candida spp. recovered from the study population
| Organism n (%) | Fluconazole* | Voriconazole* | Amphotericin B* | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| S | SDD | R | S | SDD | R | S | SDD | R | |
| C. albicans | 72 (98.6) | 0 | 1 (1.4) | 73 (100) | 0 | 0 | 73 (100) | 0 | 0 |
| NAC | 11 (37.9) | 13 (44.8) | 5 (17.2) | 29 (100) | 0 | 0 | 29 (100) | 0 | 0 |
| All Isolates | 83 (81.4) | 13 (12.7) | 6 (5.9) | 102 (100) | 0 | 0 | 102 (100) | 0 | 0 |
| Caspofungin* | Micafungin* | Flucytosine* | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| S | SDD | R | S | SDD | R | S | SDD | R | |
| C. albicans | 73 (100) | 0 | 0 | 72 (98.6) | 0 | 1 (1.4) | 73 (100) | 0 | 0 |
| NAC | 13 (44.8) | 15 (51.7) | 1 (3.4) | 27 (93.1) | 0 | 2 (6.9) | 24 (82.8) | 0 | 5 (17.2) |
| All Isolates | 86 (84.3) | 15 (14.7) | 1 (1) | 99 (97.1) | 0 | 3 (2.9) | 97 (95.1) | 0 | 5 (4.9) |
| Itraconazole# | Ketoconazole# | Clotrimazole# | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| S | SDD | R | S | SDD | R | S | SDD | R | |
| C. albicans | 66 (90.4) | 5 (6.8) | 2 (2.7) | 20 (27.4) | 30 (41.1) | 23 (31.5) | 58 (79.5) | 10 (13.7) | 5 (6.8) |
| NAC | 24 (82.8) | 4 (13.8) | 1 (3.4) | 6 (20.7) | 10 (34.5) | 13 (44.8) | 17 (58.6) | 7 (24.1) | 5 (17.2) |
| All Isolates | 90 (88.2) | 9 (8.8) | 3 (2.9) | 26 (25.5) | 40 (39.2) | 36 (35.3) | 75 (73.5) | 17 (16.7) | 10 (9.8) |
*
AST done by VITEK2
#
AST done by Disc Diffusion